Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from age-related macular degeneration, a progressive disease afflicting about 11 ...

Meibomian gland dysfunction assessments in children a highlight at the Tear Film & Ocular Surface Society's 2024 meeting.

LumiThera, Inc. today announced the U.S. FDA has authorized marketing of Valeda® Light Delivery System for patients with dry AMD.

LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024- Appointed Jason Mitchell as chief ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

The Inner Spark Sphaera has been made for athletes in need of a wide field of view. The lightweight frame features front ...

Five years ago today my family took a weekend road trip to Madison, Wisconsin for my niece’s wedding. Well, we didn’t get to attend the actual wedding (a small modern affair), but we enjoyed the ...